Uncategorized
ThromboGenics reports 15.2 million euro loss in first half
ThromboGenics reported a net loss of 15.2 million euros, or 0.42 euros per share, in the first half of 2017 compared with a net loss of 15 million euros, or 0.42 euros per share, in the first half of 2016, according to a press release.Total revenues of 2.7 million euros were reported for the 6-month period, which included 1.9 million euros worth of product sales in the United States and 0.8 million euros in royalty income from U.S. sales of Jetrea (ocriplasmin). This compares with a net income of 4 (Read more...)